Bharat Parenterals (NSE:BPLPHARMA) Tariff Resilience Score: 0/10 (As of Aug. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:BPLPHARMA Bharat Parenterals Ltd NSE:BPLPHARMA
55 GF Score
Price ₹1,294.70
GF Value ₹1,232.25
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Bharat Parenterals Tariff Resilience Score?

Bharat Parenterals has the Tariff Resilience Score of 0, which implies that the company might have .

Bharat Parenterals has

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Bharat Parenterals might have .

Bharat Parenterals  (NSE:BPLPHARMA) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Bharat Parenterals Tariff Resilience Score Related Terms

NSE:BPLPHARMA
55GF Score
Bharat Parenterals Ltd NSE:BPLPHARMA
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Bharat Parenterals (NSE:BPLPHARMA) Overvalued in 2026?

Based on GuruFocus' analysis, Bharat Parenterals stock appears to be overvalued. The current stock price of ₹1,294.70 is trading 5.1% above its estimated GF Value™ of ₹1,232.25. GuruFocus considers Bharat Parenterals to be Fairly Valued.

Key valuation signals for NSE:BPLPHARMA:

  • Tariff Resilience Score: 0
  • GF Value™: ₹1,232.25 vs. price of ₹1,294.70 (5.1% above fair value)
  • GF Score™: 55/100 with 5 warning signs

No single metric tells the full story. See the NSE:BPLPHARMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bharat Parenterals Business Description

Comparable Companies
Other Exchanges 541096:India
Address Survey No.144-A, Jarod Samlaya Road, Village Haripura, Tehsil Savli, Vadodara, GJ, IND, 391520
Bharat Parenterals Ltd is a pharmaceutical company. It provides various products such as Capsules, Dry Syrups, Sachets, Oral Liquids, Injections, Semisolids, and others. Geographically, the group has a business presence in India and Outside India.
55GF Score

Get the complete analysis for NSE:BPLPHARMA

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,294.70
Price
₹1,232.25
GF Value